Eton Pharmaceuticals
OverviewSuggest Edit
Eton Pharmaceuticals, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.
| Type | Public | |
| Founded | 2017 | |
| HQ | Palatine, IL, US | Map |
| Website | etonpharma.com |
Recent NewsAll News
- Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference
- Eton Pharmaceuticals Announces Sale of Neurology Portfolio
- Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE
- Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral Solution
Key People/Management at Eton Pharmaceuticals
Wilson Troutman
Chief Financial Officer
Sean Brynjelsen
Chief Executive Officer & Director
Norbert Riedel
Chairman of the Board
Scott Grossenbach
Vice President, Sales & Marketing
Bharathi Devarakonda
SVP, Regulatory Affairs & Product Development
David Krempa
Vice President, Business Development
Eton Pharmaceuticals Office Locations
Eton Pharmaceuticals has an office in Palatine
Palatine, IL, US (HQ)
21925 W Field Pkwy #235
Eton Pharmaceuticals Financials and Metrics
Eton Pharmaceuticals Revenue
| USD | |
|---|---|
Net income (FY, 2018) | (12.7m) |
Market capitalization (25-Feb-2021) | 199.5m |
Closing stock price (25-Feb-2021) | 8.2 |
Cash (31-Dec-2018) | 26.7m |
Eton Pharmaceuticals's current market capitalization is $199.5 m.
| USD | FY, 2017 |
|---|---|
Financial Leverage | -2 x |
Eton Pharmaceuticals Cybersecurity Score
Eton Pharmaceuticals Online and Social Media Presence
Eton Pharmaceuticals's Trends
Eton Pharmaceuticals News and Updates
February 16, 2021
Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference
DEER PARK, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that company management will be participating in the 10th An…
February 08, 2021
Eton Pharmaceuticals Announces Sale of Neurology Portfolio
DEER PARK, Ill., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has sold its neurology portfolio to Azurity Pharmace…
January 14, 2021
Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE
DEER PARK, Ill., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI® SPRINKLE fr…
December 17, 2020
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral Solution
Application Assigned a PDUFA Date of August 6, 2021 Application Assigned a PDUFA Date of August 6, 2021
November 24, 2020
Eton Pharmaceuticals Announces Availability of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) in the United States
DEER PARK, Ill., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the full availability of ALKINDI® SPRINKLE for sale and distr…
November 12, 2020
Eton Pharmaceuticals Announces Third Quarter 2020 Financial Results
DEER PARK, Ill., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today reported financial results for the third quarter ended September 30, 20…
Eton Pharmaceuticals Blogs
October 16, 2020
Eton Pharmaceuticals Announces Closing of Public Offering
Eton Pharmaceuticals Announces Closing of Public Offering
Content Import
Fri, 10/16/2020 - 16:06
Eton Pharmaceuticals Announces Closing of Public Offering
October 16, 2020 at 4:05 PM EDT
This release is a backfill from a News Wire
General
…
October 14, 2020
Eton Pharmaceuticals Prices Underwritten Public Offering of Common Stock
Eton Pharmaceuticals Prices Underwritten Public Offering of Common Stock
Content Import
Wed, 10/14/2020 - 08:31
Eton Pharmaceuticals Prices Underwritten Public Offering of Common Stock
October 14, 2020 at 8:30 AM EDT
This release is a backfill from a News Wire…
October 08, 2020
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection
Content Import
Thu, 10/08/2020 - 08:02
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection
…
October 06, 2020
Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)
Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)
Content Import
Tue, 10/06/2020 - 16:06
Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)
October 6, 2020 at 4:05 PM EDT
…
March 17, 2020
Eton Pharmaceuticals Reports Positive Study Results for ET-101 (Topiramate Oral Solution)
-Results Demonstrated Bioequivalence to the Currently Approved Oral Solid Formulation -Market for Topiramate in Oral Form is Greater than $800 million Annually DEER PARK, Ill. , March 17, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused
March 05, 2020
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results
Content Import
Thu, 03/05/2020 - 16:02
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results
March 5, 2020 at 4:02 PM EST
This release is a backfill…
Eton Pharmaceuticals Frequently Asked Questions
When was Eton Pharmaceuticals founded?
Eton Pharmaceuticals was founded in 2017.
Who are Eton Pharmaceuticals key executives?
Eton Pharmaceuticals's key executives are Wilson Troutman, Sean Brynjelsen and Norbert Riedel.
How many employees does Eton Pharmaceuticals have?
Eton Pharmaceuticals has 15 employees.
Who are Eton Pharmaceuticals competitors?
Competitors of Eton Pharmaceuticals include MyoKardia, Reata Pharmaceuticals and Biogen.
Where is Eton Pharmaceuticals headquarters?
Eton Pharmaceuticals headquarters is located at 21925 W Field Pkwy #235, Palatine.
Where are Eton Pharmaceuticals offices?
Eton Pharmaceuticals has an office in Palatine.
How many offices does Eton Pharmaceuticals have?
Eton Pharmaceuticals has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies